Storia in 2 fonti

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study - Celldex Therapeutics

Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study - Celldex Therapeutics

Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.

originale

endpoints.news1 mese fa

Celldex scraps antibody in itchy skin nodules after Phase 2 flop

Celldex's barzolvolimab failed all efficacy measures in a Phase 2 prurigo nodularis trial, focus shifts to two Phase 3 trials for chronic spontaneous urticaria.

Leggi questa versione → originale

Timeline cronologica

mercoledì 22 luglio 2026·endpoints.news
Celldex scraps antibody in itchy skin nodules after Phase 2 flop
Celldex's barzolvolimab failed all efficacy measures in a Phase 2 prurigo nodularis trial, focus shifts to two Phase 3 trials for chronic spontaneous urticaria.
mercoledì 22 luglio 2026·benzinga.com
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study - Celldex Therapeutics
Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.